Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intratumoral immunotherapy: using the tumor as the remedy
Aurélien Marabelle, Lambros Tselikas, Thierry de Baère, et al.
Annals of Oncology (2017) Vol. 28, pp. xii33-xii43
Open Access | Times Cited: 306

Showing 1-25 of 306 citing articles:

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed, Lieping Chen
Cell (2018) Vol. 175, Iss. 2, pp. 313-326
Open Access | Times Cited: 1183
Cancer nanomedicine for combination cancer immunotherapy
Jutaek Nam, Sejin Son, Kyong Soo Park, et al.
Nature Reviews Materials (2019) Vol. 4, Iss. 6, pp. 398-414
Closed Access | Times Cited: 809
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
Claudio Luchini, Frédéric Bibeau, M. Ligtenberg, et al.
Annals of Oncology (2019) Vol. 30, Iss. 8, pp. 1232-1243
Open Access | Times Cited: 809
Harnessing innate immunity in cancer therapy
Olivier Demaria, Stéphanie Cornen, Marc Daëron, et al.
Nature (2019) Vol. 574, Iss. 7776, pp. 45-56
Closed Access | Times Cited: 751
Optimizing oncolytic virotherapy in cancer treatment
Kevin J. Harrington, Daniel J. Freeman, Elizabeth J. Kelly, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 9, pp. 689-706
Closed Access | Times Cited: 426
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Alan J. Korman, Sarah C. Garrett-Thomson, Nils Lönberg
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 7, pp. 509-528
Closed Access | Times Cited: 373
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Ignacio Melero, Eduardo Castañón, Maite Álvarez, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 9, pp. 558-576
Open Access | Times Cited: 341
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 293
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Pier Francesco Ferrucci, Laura Pala, Fabio Conforti, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1383-1383
Open Access | Times Cited: 220
Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy
David M. Francis, Margaret P. Manspeaker, Alex Schudel, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 563
Open Access | Times Cited: 189
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Aurélien Marabelle, Robert Hans Ingemar Andtbacka, Kevin J. Harrington, et al.
Annals of Oncology (2018) Vol. 29, Iss. 11, pp. 2163-2174
Open Access | Times Cited: 178
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
Ravi B. Patel, Reinier Hernandez, Peter M. Carlson, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 602
Open Access | Times Cited: 154
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Qiang Lü, Dongquan Kou, Shenghan Lou, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 131
Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity
Yash Agarwal, Lauren E. Milling, Jason Y.H. Chang, et al.
Nature Biomedical Engineering (2022) Vol. 6, Iss. 2, pp. 129-143
Open Access | Times Cited: 96
ER-Targeting PDT Converts Tumors into In Situ Therapeutic Tumor Vaccines
Xu Liu, Yu Liu, Xiang Li, et al.
ACS Nano (2022) Vol. 16, Iss. 6, pp. 9240-9253
Closed Access | Times Cited: 93
An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy
Shuhan Liu, Ji Liu, Haisong Li, et al.
Biomaterials (2022) Vol. 287, pp. 121645-121645
Closed Access | Times Cited: 76
Enhancing in situ cancer vaccines using delivery technologies
Ningqiang Gong, Mohamad‐Gabriel Alameh, Rakan El‐Mayta, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 8, pp. 607-625
Closed Access | Times Cited: 25
Cancer Nanovaccines: Nanomaterials and Clinical Perspectives
Nimeet Desai, Vivek P. Chavda, Thakur Raghu Raj Singh, et al.
Small (2024) Vol. 20, Iss. 35
Open Access | Times Cited: 23
Locoregional drug delivery for cancer therapy: Preclinical progress and clinical translation
Suyog Shaha, Danika Rodrigues, Samir Mitragotri
Journal of Controlled Release (2024) Vol. 367, pp. 737-767
Closed Access | Times Cited: 20
Nanoparticle‐Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses
Lutz Nuhn, Stefaan De Koker, Sandra Van Lint, et al.
Advanced Materials (2018) Vol. 30, Iss. 45
Closed Access | Times Cited: 140
Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
Zhiyong Wang, Victoria H. Wu, Michael M. Allevato, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 140
Intratumoral Immunotherapy for Early-stage Solid Tumors
Wan Xing Hong, Sarah Haebe, Andrew S. Lee, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 13, pp. 3091-3099
Open Access | Times Cited: 136
Intratumoral Immunotherapy—Update 2019
Omid Hamid, Rubina Ismail, Igor Puzanov
The Oncologist (2019) Vol. 25, Iss. 3, pp. e423-e438
Open Access | Times Cited: 134
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
Oliver Kepp, Aurélien Marabelle, Laurence Zitvogel, et al.
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 1, pp. 49-64
Closed Access | Times Cited: 126
The Promise of Combining Radiation Therapy With Immunotherapy
Justin C. Jagodinsky, Paul M. Harari, Zachary S. Morris
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 108, Iss. 1, pp. 6-16
Open Access | Times Cited: 123
Page 1 - Next Page

Scroll to top